院長紹介

主な業績 英文原著 

Minimal residual B cell function is importamt in metabolic stability in IDDM. Resent trends in management of diabetes mellitus,   Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yodosawa K, Yamamoto Y, Kunahara Y, and Shima K., 1987. :p. 368-370.

Correlation between minimal secretory capacity of pancreatic beta cells and stability of diabetic control  Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, and Shima K., Diabetes, 1988. 37: p. 81-88.

Effect of very-low-calorie diet weight reduction on glucose tolerance, insulin secretion, and insulin resistance in obese non-insulin-dependent diabetes.  Fukuda M, Tahara Y, Yamamoto Y, Onishi T, Kumahara Y, Tanaka A, and Shima K.,  Diab Res Clin Prac, 1989. 7: p. 61-67.

A case with hyperinsulineamia due to hypersecretion of incretin. prevention of treatment of NIDDM,  Fukuda M, Ikegami H, Hotta M, Yamato E, Cha T, Kawaguchi Y, Tahara Y, Fujioka Y, Morimoto S, Shima K, and Ogihara T., ed. Goto Y, et al. 1992, London: Smith-Gordon. 97-99.

Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Fukuda M, Ikegami H, Kawaguchi Y, Sano T, Ogihara T. Biochem Biophys Res Commun. 1995 26;209(3):953-8.

Aspartame-Acesulfame K-containing Low-Energy Erythritol Sweetener Markedly Suppresses Postprandial Hyperglycemia in Mild and Borderline Diabetics    Fukuda M, Terata T, Tsuda K, Kitatani N and Seino Y. ood science and technology research 16(5), 457-466, 2010

Survey of Hypoglycemia in Elderly People With Type 2 Diabetes Mellitus in Japan.  Fukuda M1, Doi K2, Sugawara M3, Naka Y4, Mochizuki K5.  J Clin Med Res. 2015 Dec;7(12):967-78. doi: 10.14740/jocmr2340w. Epub 2015 Oct 23.

8.Fukuda M(1), Doi K, Sugawara M, Mochizuki K.  Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: a focus on hypoglycemia.  J Diabetes Investig. 2018 Aug 23. doi: 10.1111/jdi.12915. [Epub ahead of print].

Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: Ken Sugimoto  1 , Yasuharu Tabara  2 , Hiroshi Ikegami  3 , Yasunori Takata  4 , Kei Kamide  5 , Tome Ikezoe  6 , Eri Kiyoshige  5 , Yukako Makutani  3 , Hiroshi Onuma  7 , Yasuyuki Gondo  8 , Kazunori Ikebe  9 , Noriaki Ichihashi  6 , Tadao Tsuboyama  6   10 , Fumihiko Matsuda  2 , Katsuhiko Kohara  11 , Mai Kabayama  5 , Masahiro Fukuda  12 , Tomohiro Katsuya  13   14 , Haruhiko Osawa  4 , Yoshihisa Hiromine  3 , Hiromi Rakugi  1

J Diabetes Investig Nov;10(6):1471-1479. doi: 10.1111/jdi.13070. Epub 2019 Jun 1.

Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study  Takashi Sasaki and Masahiro Sugawara and Masahiro Fukuda Journal of Diabetes Investigation 2019-01-16 | journal-article

Effect of tasteless calorie-free gum chewing before meal on postprandial plasma glucose, insulin, glucagon, and gastrointestinal hormones in Japanese men without diagnosed glucose metabolism disorder: a pilot randomized crossover trial  Mitsuyoshi Takahara #  1 , Masahiro Fukuda #  2 , Yuji Matsuzawa  3 , Iichiro Shimomura  4 Diabetol Int .11(4): 394-402 2020

Glycemic Control and Insulin Improve Muscle Mass and Gait Speed in Type 2 Diabetes: The MUSCLES-DM Study  Ken Sugimoto MD a, Hiroshi Ikegami MD b, Yasunori Takata MD c, Tomohiro Katsuya MD d, e, Masahiro Fukuda MD f, Hiroshi Akasaka MD a, Yasuharu Tabara PhD g, Haruhiko Osawa MD c, Yoshihisa Hiromine MD b, Hiromi Rakugi MDa,* VOLUME 22, ISSUE 4, P834-838.E1, APRIL 01, 2021DOI:https://doi.org/10.1016/j.jamda.2020.11.003 10.1016/j.jamda.2020.11.003

Correlation Between Changes in the Serum Magnesium Concentration and Visceral Fat Volume in Patients With Type 2 Diabetes Receiving Luseogliflozin: A Sub-Analysis of Data From the LIGHT Study  Tatsuo Yanagawa, Hideshi Matsuda, Masahiro Sugawara, Masahiro Fukuda, Takashi SasakiJournal of Endocrinology and Metabolism Volume 11, Number 2, p 35-41 2021

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)  Masahiro Sugawara , Masahiro Fukuda , Ichiro Sakuma et al   Diabetes Ther. 2023 Sep;14(9):1517-1535. doi: 10.1007/s13300-023-01438-w. Epub 2023 Jul 6.

Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)
Masahiro Fukuda 1, Ichiro Sakuma 2, Yutaka Wakasa 3, Hideaki Funayama 4, Akira Kondo 5, Naoki Itabashi 6, Yasuyuki Maruyama 7, Takashi Kamiyama 8, Yasunori Utsunomiya 9, Akira Yamauchi 10, Hidenori Yoshii 11, Hirokazu Yamada 12, Koichi Mochizuki 13, Masahiro Sugawara 1

Diabetes Ther  . 2024 Jun;15(6):1403-1416.   doi: 10.1007/s13300-024-01575-w.Epub 2024 Apr 24.